Results 21 to 30 of about 58,868 (161)

Therapeutic Potential of IL-15 and N-803 in HIV/SIV Infection

Viruses, 2021
IL-15, a proinflammatory cytokine critical for the generation, maintenance, and homeostasis of T cell responses, is produced naturally in response to HIV/SIV infection, but has also demonstrated therapeutic potential. IL-15 can boost CD4+ and CD8+ T cell
Olivia E. Harwood, Shelby L. O’Connor
semanticscholar   +1 more source

The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques

PLoS Pathogens, 2020
Despite the success of antiretroviral therapy (ART) to halt viral replication and slow disease progression, this treatment is not curative and there remains an urgent need to develop approaches to clear the latent HIV reservoir.
G. Webb, Jhomary S Molden, K. Busman-Sahay, S. Abdulhaqq, Helen L. Wu, W. Weber, K. Bateman, J. Reed, M. Northrup, Nicholas Maier, Shiho Tanaka, Lina Gao, B. Davey, B. Carpenter, M. Axthelm, J. Stanton, J. Smedley, J. Greene, J. Safrit, J. Estes, P. Skinner, J. Sacha   +21 more
semanticscholar   +1 more source

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil [PDF]

Anais Brasileiros de Dermatologia
: Background: Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. Objective: The authors
Tania F. Cestari, Cacilda da Silva Souza, Luna Azulay-Abulafia, Ricardo Romiti, André V.E. Carvalho, Caio César Silva de Castro, Sílvio Alencar Marques, João Roberto Antonio, Lincoln Fabrício, Ahmed M. Soliman, Tianshuang Wu, Ranjeeta Sinvhal, Vassilis Stakias, Alexandra P. Song, Jasmina Kalabic, Naomi Martin, Luiza Keiko Matsuka Oyafuso   +16 more
doaj   +1 more source

N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review

Future Oncology
Summary What is this summary about? This is a summary of two studies that looked at the safety and effectiveness of a potential new treatment, N-803 (Anktiva), in combination with a standard treatment bacillus Calmette-Guerin (BCG) for people with non ...
K. Chamie, Sam S. Chang, C. Rosser, Eugene Kramolowski, M. Gonzalgo, W. Sexton, Patricia Spilman, Lennie Sender, Sandeep Reddy, P. Soon-Shiong   +9 more
semanticscholar   +1 more source

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Blood, 2018
New therapies for patients with hematologic malignancies who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) are needed. Interleukin 15 (IL-15) is a cytokine that stimulates CD8+ T-cell and natural killer (NK) cell antitumor ...
R. Romee, S. Cooley, M. Berrien-Elliott, P. Westervelt, M. Verneris, J. Wagner, D. Weisdorf, B. Blazar, C. Ustun, T. Defor, Sithara Vivek, L. Peck, J. Dipersio, A. Cashen, R. Kyllo, A. Musiek, A. Schaffer, M. Anadkat, I. Rosman, Daniel Miller, J. Egan, Emily K. Jeng, A. Rock, H. Wong, T. Fehniger, Jeffrey S. Miller   +25 more
semanticscholar   +1 more source

Combination of CD8β Depletion and Interleukin-15 Superagonist N-803 Induces Virus Reactivation in Simian-Human Immunodeficiency Virus-Infected, Long-Term ART-Treated Rhesus Macaques

Journal of Virology, 2020
The “shock and kill” HIV cure strategy attempts to reverse and eliminate the latent viral infection that prevents eradication of the virus. Latency-reversing agents tested in clinical trials to date have failed to affect the HIV viral reservoir.
J. McBRIEN, A. I. Wong, E. White, D. Carnathan, John-hwa Lee, J. Safrit, T. Vanderford, M. Paiardini, A. Chahroudi, G. Silvestri   +9 more
semanticscholar   +1 more source

Clinical and epidemiological characterization of patients with cutaneous tuberculosis treated at a referral center in the Brazilian Amazon: case series [PDF]

Anais Brasileiros de Dermatologia
Background: Cutaneous tuberculosis is a rare form of the disease that defies diagnosis due to the diversity of clinical presentations. This study was based on the reality of a dermatology referral center in the Brazilian Amazon region to detail several ...
Letícia Rezende da Silva Sobral, Isabela de Nazaré Tavares Cardoso Souza, Maria Fernanda de Almeida Cavalcante Aranha, Ana Beatriz Dias Silva, Maria Amélia Lopes dos Santos, Renata Mie Oyama Okajima, Francisca Regina Oliveira Carneiro, Carla Andréa Avelar Pires   +7 more
doaj   +1 more source

Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts

Molecular therapy. Oncology
The prognosis for children with recurrent and/or refractory neuroblastoma (NB) is dismal. The receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is highly expressed on the surface of NB cells, provides a potential target for novel ...
Y. Chu, Gaurav Nayyar, M. Tian, D. Lee, Mehmet F. Ozkaynak, Jessica Ayala-Cuesta, K. Klose, Keira Foley, Alyssa S. Mendelowitz, W. Luo, Y. Liao, J. Ayello, Gregory Behbehani, Stanley R. Riddell, T. Cripe, Mitchell S. Cairo   +15 more
semanticscholar   +1 more source

IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells

Cancer Immunology and Immunotherapy, 2020
Allogeneic natural killer (NK) cell transfer is a potential immunotherapy to eliminate and control cancer. A promising source are CD34 + hematopoietic progenitor cells (HPCs), since large numbers of cytotoxic NK cells can be generated. Effective boosting
J. V. D. Meer, R. Maas, K. Guldevall, K. Klarenaar, Paul De Jonge, J. Evert, A. B. V. D. Waart, J. Cany, J. Safrit, J. H. Lee, E. Wagena, Peter Friedl, B. Önfelt, L. Massuger, N. Schaap, J. Jansen, W. Hobo, H. Dolstra   +17 more
semanticscholar   +1 more source

Interference of the positioning of nickel, chromium and cobalt in the results of patch tests [PDF]

Anais Brasileiros de Dermatologia
Background: The positioning of substances, which are co-sensitizers and/or with a tendency to cross-react, is not considered in the technique when applying patch tests (PT).
Ida Duarte, Rosana Lazzarini, Mariana Haffner, Julia P. Silva   +3 more
doaj   +1 more source